Inovio Pharmaceuticals Acquires Needle-Free Injection Technology to Advance Strategy for Next-Generation Vaccines

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Inovio Pharmaceuticals Acquires Needle-Free Injection Technology to Advance Strategy for Next-Generation Vaccines

Maxim Affirms Inovio Pharma (INO) at 'Buy' Following Q4 Results, Asset Acquisition

March 14, 2016 2:45 PM EDT

Maxim affirmed Inovio Pharma (Nasdaq: INO) with a Buy rating and $14 price target following Q4 results and acquisition of Bioject Medical Technologies' Needle-Free Injection Technology earlier Monday.

Analyst Jason Kolbert noted the following

Immune oncology: A phase III study for VGX-3100 is expected... More